Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.56 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | EPHX2 | P34913 | 7/20 | 0.45 |
| ▸ | EPHX1 | P07099 | 3/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13853824 | 0.86 | KDM4E (0.55) | KDM4EALDH1A1EPHX2HTTPOLB | |
| SCHEMBL1918845 | 0.85 | KDM4E (0.61) | KDM4EALDH1A1CYP1A2TDP1EPHX2 | |
| SCHEMBL26826602 | 0.83 | KDM4E (0.52) | KDM4EALDH1A1EPHX2EPHX1 | |
| SCHEMBL26814552 | 0.83 | KDM4E (0.52) | KDM4EALDH1A1EPHX2HTTPOLB | |
| SCHEMBL14417946 | 0.83 | KDM4E (0.72) | KDM4EALDH1A1CYP1A2TDP1EPHX2 | |
| SCHEMBL18389971 | 0.81 | KDM4E (0.74) | KDM4EALDH1A1CYP1A2TDP1EPHX2 | |
| SCHEMBL26816653 | 0.79 | KDM5A (0.49) | ALDH1A1EPHX2EPHX1KDM5B | |
| SCHEMBL17037034 | 0.79 | CA1 (0.54) | EPHX2EPHX1 | |
| SCHEMBL9640396 | 0.79 | CA1 (0.54) | EPHX2EPHX1 | |
| SCHEMBL5746611 | 0.78 | EPHX2 (0.51) | EPHX2EPHX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11827640-B2 | Substituted pyrazolo[1,5-a]pyrimidines as CFTR modulators | ILDONG PHARMACEUTICAL CO., LTD. (KR) | 2023-11-28 | — | — | US | disclosed |
| US-11827640-B2 | Substituted pyrazolo[1,5-a]pyrimidines as CFTR modulators | ILDONG PHARMACEUTICAL CO., LTD. (KR) | 2023-11-28 | — | — | US | disclosed |
| WO-2022084741-A1 | CFTR MODULATOR COMPOUNDS, COMPOSITIONS, AND USES THEREOF | ILDONG PHARMACEUTICAL CO., LTD. (KR) | 2022-04-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11827640-B2 | Substituted pyrazolo[1,5-a]pyrimidines as CFTR modulators | PDE4A, PDE4B, PDE5A | KDM4E 2287/4885ALDH1A1 983/4885CYP1A2 1431/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.